Prostate cancer progression:: Sodium salicylate, the active metabolite of aspirin inhibits nuclear factor-kappa B (NFkB) pathway

Olaniyi Ogundiya; Helen Whiteland; U. K. Shah; O. Bodger; H. Haboubi; H. Kynaston; S. Doak

doi:10.1016/j.ijsu.2018.05.038

Abstract

Aim: Evidence from several studies suggests that nuclear factor-kappa B (NFκB) pathway is associated with cancer progression. Therefore, the inhibition of the NFκB pathway provides the focus for cancer management. Sodium salicylate, the active metabolite of aspirin has been shown to inhibit NFκB activation in prostate cell lines. In this study, we examine the role of NFκB pathway in PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis).

Method: We exposed both normal prostate (PNT2) cells and prostate cancer (DU145, PC3) cell lines to sodium salicylate. NFκB activation in prostate cells was examined by ELISA (enzyme-linked immunosorbent assay) alongside controls. IKK an inhibitor of NFκB activation and tumour necrosis factor (TNF) a potent activator of NFκB were utilised as controls.

Result: Our results suggest that sodium salicylate inhibits NFκB activation in prostate cancer cell lines. PC3 (the most aggressive cell line) showed a decreased level of NFκB activation after treatment with sodium salicylate. However, PNT2 and DU145 showed very little change in NFκB activation over the dose ranges applied.

Conclusion: Our study provides further evidence that NFκB pathway is associated with prostate cancer progression as we observed NFκB activation and inhibition by sodium salicylate in all three prostatic cell lines.

Original language	English
Pages	S13-S14
Number of pages	2
DOIs	https://doi.org/10.1016/j.ijsu.2018.05.038
Publication status	E-pub ahead of print - 02 Aug 2018
Event	Association of Surgeons In Training International Surgical Conference 2018 - Edinburgh International conference Centre, Edinburgh, United Kingdom of Great Britain and Northern Ireland Duration: 06 Apr 2018 → 08 Apr 2018

Conference

Conference	Association of Surgeons In Training International Surgical Conference 2018
Abbreviated title	ASiT
Country/Territory	United Kingdom of Great Britain and Northern Ireland
City	Edinburgh
Period	06 Apr 2018 → 08 Apr 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ijsu.2018.05.038

Permanent link

Persistent link

Cite this

Ogundiya, O., Whiteland, H., Shah, U. K., Bodger, O., Haboubi, H., Kynaston, H., & Doak, S. (2018). Prostate cancer progression: Sodium salicylate, the active metabolite of aspirin inhibits nuclear factor-kappa B (NFkB) pathway. S13-S14. Abstract from Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, United Kingdom of Great Britain and Northern Ireland. https://doi.org/10.1016/j.ijsu.2018.05.038

@conference{8cd815cb46a0416b9ad6312295247b61,

title = "Prostate cancer progression:: Sodium salicylate, the active metabolite of aspirin inhibits nuclear factor-kappa B (NFkB) pathway",

abstract = "Aim: Evidence from several studies suggests that nuclear factor-kappa B (NFκB) pathway is associated with cancer progression. Therefore, the inhibition of the NFκB pathway provides the focus for cancer management. Sodium salicylate, the active metabolite of aspirin has been shown to inhibit NFκB activation in prostate cell lines. In this study, we examine the role of NFκB pathway in PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis).Method: We exposed both normal prostate (PNT2) cells and prostate cancer (DU145, PC3) cell lines to sodium salicylate. NFκB activation in prostate cells was examined by ELISA (enzyme-linked immunosorbent assay) alongside controls. IKK an inhibitor of NFκB activation and tumour necrosis factor (TNF) a potent activator of NFκB were utilised as controls.Result: Our results suggest that sodium salicylate inhibits NFκB activation in prostate cancer cell lines. PC3 (the most aggressive cell line) showed a decreased level of NFκB activation after treatment with sodium salicylate. However, PNT2 and DU145 showed very little change in NFκB activation over the dose ranges applied.Conclusion: Our study provides further evidence that NFκB pathway is associated with prostate cancer progression as we observed NFκB activation and inhibition by sodium salicylate in all three prostatic cell lines.",

author = "Olaniyi Ogundiya and Helen Whiteland and Shah, {U. K.} and O. Bodger and H. Haboubi and H. Kynaston and S. Doak",

year = "2018",

month = aug,

day = "2",

doi = "10.1016/j.ijsu.2018.05.038",

language = "English",

pages = "S13--S14",

note = "Association of Surgeons In Training International Surgical Conference 2018, ASiT ; Conference date: 06-04-2018 Through 08-04-2018",

}

Ogundiya, O, Whiteland, H, Shah, UK, Bodger, O, Haboubi, H, Kynaston, H & Doak, S 2018, 'Prostate cancer progression: Sodium salicylate, the active metabolite of aspirin inhibits nuclear factor-kappa B (NFkB) pathway', Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, United Kingdom of Great Britain and Northern Ireland, 06 Apr 2018 - 08 Apr 2018 pp. S13-S14. https://doi.org/10.1016/j.ijsu.2018.05.038

Prostate cancer progression: Sodium salicylate, the active metabolite of aspirin inhibits nuclear factor-kappa B (NFkB) pathway. / Ogundiya, Olaniyi; Whiteland, Helen; Shah, U. K. et al.

2018. S13-S14 Abstract from Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, United Kingdom of Great Britain and Northern Ireland.

Research output: Contribution to conference › Abstract › peer-review

TY - CONF

T1 - Prostate cancer progression:

T2 - Association of Surgeons In Training International Surgical Conference 2018

AU - Ogundiya, Olaniyi

AU - Whiteland, Helen

AU - Shah, U. K.

AU - Bodger, O.

AU - Haboubi, H.

AU - Kynaston, H.

AU - Doak, S.

PY - 2018/8/2

Y1 - 2018/8/2

N2 - Aim: Evidence from several studies suggests that nuclear factor-kappa B (NFκB) pathway is associated with cancer progression. Therefore, the inhibition of the NFκB pathway provides the focus for cancer management. Sodium salicylate, the active metabolite of aspirin has been shown to inhibit NFκB activation in prostate cell lines. In this study, we examine the role of NFκB pathway in PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis).Method: We exposed both normal prostate (PNT2) cells and prostate cancer (DU145, PC3) cell lines to sodium salicylate. NFκB activation in prostate cells was examined by ELISA (enzyme-linked immunosorbent assay) alongside controls. IKK an inhibitor of NFκB activation and tumour necrosis factor (TNF) a potent activator of NFκB were utilised as controls.Result: Our results suggest that sodium salicylate inhibits NFκB activation in prostate cancer cell lines. PC3 (the most aggressive cell line) showed a decreased level of NFκB activation after treatment with sodium salicylate. However, PNT2 and DU145 showed very little change in NFκB activation over the dose ranges applied.Conclusion: Our study provides further evidence that NFκB pathway is associated with prostate cancer progression as we observed NFκB activation and inhibition by sodium salicylate in all three prostatic cell lines.

AB - Aim: Evidence from several studies suggests that nuclear factor-kappa B (NFκB) pathway is associated with cancer progression. Therefore, the inhibition of the NFκB pathway provides the focus for cancer management. Sodium salicylate, the active metabolite of aspirin has been shown to inhibit NFκB activation in prostate cell lines. In this study, we examine the role of NFκB pathway in PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis).Method: We exposed both normal prostate (PNT2) cells and prostate cancer (DU145, PC3) cell lines to sodium salicylate. NFκB activation in prostate cells was examined by ELISA (enzyme-linked immunosorbent assay) alongside controls. IKK an inhibitor of NFκB activation and tumour necrosis factor (TNF) a potent activator of NFκB were utilised as controls.Result: Our results suggest that sodium salicylate inhibits NFκB activation in prostate cancer cell lines. PC3 (the most aggressive cell line) showed a decreased level of NFκB activation after treatment with sodium salicylate. However, PNT2 and DU145 showed very little change in NFκB activation over the dose ranges applied.Conclusion: Our study provides further evidence that NFκB pathway is associated with prostate cancer progression as we observed NFκB activation and inhibition by sodium salicylate in all three prostatic cell lines.

U2 - 10.1016/j.ijsu.2018.05.038

DO - 10.1016/j.ijsu.2018.05.038

M3 - Abstract

SP - S13-S14

Y2 - 6 April 2018 through 8 April 2018

ER -

Ogundiya O, Whiteland H, Shah UK, Bodger O, Haboubi H, Kynaston H et al.. Prostate cancer progression: Sodium salicylate, the active metabolite of aspirin inhibits nuclear factor-kappa B (NFkB) pathway. 2018. Abstract from Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, United Kingdom of Great Britain and Northern Ireland. Epub 2018 Aug 2. doi: 10.1016/j.ijsu.2018.05.038

Prostate cancer progression: Sodium salicylate, the active metabolite of aspirin inhibits nuclear factor-kappa B (NFkB) pathway